Trinity Delta Lighthouse: Nexstim
Trinity Delta view: A major focus area for Nexstim is gaining market traction with its NBT platform in MDD. Good momentum is being shown so far: FY19 NBT Therapy sales grew +131% to €1.5m. Growing usage generates more patient registry data, and this valuable clinical evidence, whether published in white papers or journals, will support marketing efforts to drive further adoption. While the COVID-19 pandemic will have repercussions on commercial activities, we note that core NBT use in MDD is in out-patient psychiatric clinics/TMS centres with an active installed base of 23 systems at end-FY19. Nexstim also continues to explore potential entry into a distinct new in-patient TMS market: treating hospitalised severe MDD patients who may have suicidal ideation. NBT would be well suited given intensive treatment protocols and a need for accurate targeting.Nexstim’s strategic review and update is expected to conclude in the spring. This aims to refine the long-term outlook and financial objectives across the Therapy (NBT) and Diagnostics (NBS) businesses and includes evaluating various funding options and strategic alternatives. Ahead of this, we maintain our €31.4m (€0.50/share) valuation.
Nexstim Oyj. Nexstim Oyj is a Finland-based medical technology company. It is focused on improving rehabilitation for stroke patients through the use of noninvasive brain stimulation. Its offering comprises: a diagnostic tool for brain surgery planning, Navigated Brain Stimulation (NBS) System, which comprises navigated transcranial magnetic stimulation (nTMS) device for presurgical mapping (PSM) of the motor and speech cortices; and a device for stroke therapy called Navigated Brain Therapy (NBT) System, which focuses stimulation on targeted locations in the brain in order to enhance rehabilitation process. The NBT System targets upper limb motor disability and is under Phase III pivotal clinical trial study at rehabilitation sites in the United States. The Company's systems are used in over 100 facilities in research, therapy and neurosurgical planning purposes. Nexstim Oyj has two subsidiaries: Nexstim Inc and Nexstim Germany GmbH.
We are experienced healthcare and life sciences analysts providing the highest quality service to companies in these sectors and to investors. We have expertise in the fields of the biotech, medtech , specialty pharma and consumer health sectors.
The old-fashioned values of the City enabled London to become a global financial centre, and we pride ourselves for our integrity and professionalism, where our word is our bond. This applies to our research, and all interactions with companies, the buyside and other partners.
We also firmly believe that by putting our clients first, we create long term value for all stakeholders.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.